TCL Archive Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial April 27, 2012
TCL Archive In Brief: O’Conor Now Top Prospect If Rauscher Leaves; Flood Gives NCI Increase Of Only $11 Million May 14, 1976
TCL Archive In Brief: Top Priority: Keep Rauscher; Pay Raise Bill No Moving; Miller, Holland Head AACR, ASCO May 21, 1976
TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
